Europe
UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.
Moderna is working with international regulators to accelerate approval of the company’s COVID-19 vaccine candidate, mRNA-1273.
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES